BioPorto A/S 2025 AR2
The report highlights BioPorto's solid performance in 2025, achieving 11% sales growth driven by its research use only NGAL business in the US. The company successfully launched ProNephro AKI on the Roche Cobas c 501 module for the US pediatric market and completed patient enrolment in its clinical cut-off study. BioPorto refined its 'Forward' strategy to focus on market adoption, aiming for positive cash flow in late 2027. Additionally, the company raised DKK 77 million through private placements to secure its financial needs through 2026.
Company: BioPorto A/S
Sector: Professional & technical services
Country: Denmark
Year: 2025
Type: AR2
Pages: 92
Back to company
BioPorto A/S
Annual Report
The report highlights BioPorto's solid performance in 2025, achieving 11% sales growth driven by its research use only NGAL business in the US. The company successfully launched ProNephro AKI on the Roche Cobas c 501 module for the US pediatric market and completed patient enrolment in its clinical cut-off study. BioPorto refined its 'Forward' strategy to focus on market adoption, aiming for positive cash flow in late 2027. Additionally, the company raised DKK 77 million through private placements to secure its financial needs through 2026.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees